Males/females | Age years | FEV1 L | FEV1 %pred | FVC L | FEV1/FVC ratio | Smoking history pack-years | Lung cancer lesion | Recorded medications | |||
SAB | LAB | ICS | |||||||||
COPD, current smoker | 10/6 | 70.9 (60–82) | 1.9 (0.9–3.5) | 74.6 (53–96) | 3.3 (1.7–5.4) | 59.0 (46–75) | 56.9 (9–124) | Yes | 7 | 4 | 4 |
COPD, ex-smoker | 17/2 | 72.1 (60–80) | 1.7 (1.3–2.5) | 64.8 (45–118) | 3.0 (2.4–4.5) | 56.3 (42.5–69.3) | 48.7 (11–112) | Yes | 9 | 12 | 9 |
No airflow obstruction, current smoker | 4/13 | 64.4 (44–78) | 2.3 (1.6–3.3) | 105.2 (70–131) | 3.1 (2.1–4.4) | 73.1 (66.9–82.5) | 44.2 (15–90) | Yes | 0 | 0 | 0 |
No airflow obstruction, ex-smoker | 9/8 | 72.1 (57–84) | 2.1 (1.2–3.2) | 91.9 (47–127) | 2.9 (1.8–4.1) | 71.2 (55–85.8) | 37.3 (2.1–117) | Yes | 1 | 1 | 1 |
Never smoker | 0/3 | 68.3 (65–71) | 1.9 (1.8–2.0) | 108.3 (100–113) | 2.7 (2.2–3.6) | 82.5 (77–91) | 0 (0) | Yes | 1 | 0 | 1 |
Average for lung cancer group | 40/32 (total) | 69.8 (44–84) | 2.0 (0.87–3.5) | 84.8 (45–131) | 3.1 (1.69–5.4) | 65.5 (42.5–90.9) | 44.1 (0–124) | Yes | 18 | 17 | 15 |
Healthy, never smoker controls | 7/3 | 52.2 (31–75) | 3.3 (2.3–4.18) | 107 (82.7–148.6) | 4.3 (2.9–5.6) | 78.6 (70.8–95.1) | 0.0 (0) | No | 0 | 0 | 0 |
Subject demographics of cancer patients (n=72) and healthy nonsmoker control subjects (n=10). Data are presented as the mean (range) or n. FEV1: forced expired volume in 1 s; FVC: forced vital capacity; SAB: short-acting bronchodilators; LAB: long-acting bronchodilators; ICS: inhaled corticosteroid.